Video Highlights
2:08 Cornelius (Neil) Clancy, MD
4:29 David Hyun, MD
6:13 Christopher Burns, PhD
6:48 Guy Palmer, DVM, PhD
|Videos|November 18, 2021
What is the Medical Community’s Awareness on Antimicrobial Resistance?
Author(s)John Parkinson
Providers and key stakeholders weigh in on this significant topic.
Advertisement
Welcome to our series, 1 Big Question, which asks 1 question to the medical community and we get their feedback on an important infectious disease topic.
In this episode, our 1 Big Question is: Do you get the sense that the overall medical community understands the magnitude of the problem of antimicrobial resistance from a big picture standpoint?
We interviewed Cornelius (Neil) Clancy, MD, an associate professor of medicine and director of the Mycology Program at the University of Pittsburgh, David Hyun, MD, project director, Antibiotic Resistance Project,
Check out our video to hear their insights.
Advertisement
Related to this article
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
Widespread antimicrobial use disrupts vital microbial communities that regulate Earth’s biogeochemical cycles, driving antimicrobial resistance, worsening human and environmental health, and significantly contributing to climate change.
New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.
Outcomes from treating orthopedic infection with debridement and implanted antibiotic were similar whether followed by short or standard duration of systemic antibiotic.
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Advertisement
Advertisement
Trending on Contagion Live
1
Measles Update: September 25, 2026
2
US Company Recalls Thousands of Pounds of Uninspected Meat
3
Carbapenem-Sparing Therapy for ESBL Bacteremia: New Trials, Old Questions
4
Enivronmental Stewardship: The Role of Antimicrobials in Climate Change
5